Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 7/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 2/20 | 0.41 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
| ▸ | LSS | P48449 | 1/20 | 0.39 |
| ▸ | NNMT | P40261 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1092092 | 0.82 | MAPT (0.62) | GPR119GABRA5MAPTACACBNNMT | |
| SCHEMBL1390119 | 0.80 | NNMT (0.60) | MAPTNNMT | |
| SCHEMBL1092214 | 0.80 | MAPT (0.48) | ACHEGABRA5MAPTACACBLSS | |
| SCHEMBL795937 | 0.79 | MAPT (0.61) | ACHEGABRA5MAPTACACBPARP15 | |
| SCHEMBL13194647 | 0.78 | MAPT (0.47) | ACHEMAPTLSSNNMT | |
| SCHEMBL19834486 | 0.78 | ACACA (0.63) | GPR119GABRA5ACACB | |
| SCHEMBL16762041 | 0.78 | MAPT (0.40) | GPR119GABRA5MAPTLSSNNMT | |
| SCHEMBL17220078 | 0.77 | ACHE (0.49) | ACHEGABRA5MAPTACACBPARP15 | |
| SCHEMBL2713528 | 0.77 | L3MBTL1 (0.63) | MAPT | |
| SCHEMBL15351489 | 0.77 | GPR119 (0.41) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339169-B2 | P2X3 and/or P2X2/3 compounds and methods | ASANA BIOSCIENCES, LLC (US) | 2022-05-24 | — | — | US | disclosed |
| US-20200190096-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC | 2020-06-18 | — | — | US | disclosed |
| US-10611768-B2 | P2X3 and/or P2X2/3 compounds and methods | ASANA BIOSCIENCES, LLC (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190092778-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC | 2019-03-28 | — | — | US | disclosed |
| US-10174039-B2 | P2X3 and/or P2X2/3 compounds and methods | ASANA BIOSCIENCES, LLC (US) | 2019-01-08 | — | — | US | disclosed |
| WO-2018064135-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC (US) | 2018-04-05 | — | — | WO | disclosed |
| US-20180093991-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC | 2018-04-05 | — | — | US | disclosed |
| US-20180093991-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093991-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | P2RX3, P2RX6, P2RX2 | GPR119 315/4885ACHE 399/4885GABRA5 451/4885 |
| US-11339169-B2 | P2X3 and/or P2X2/3 compounds and methods | P2RX3, P2RX6, P2RX2 | GPR119 315/4885ACHE 399/4885GABRA5 451/4885 |
| US-20200190096-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | P2RX3, P2RX6, P2RX2 | GPR119 315/4885ACHE 399/4885GABRA5 451/4885 |
| US-20190092778-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | P2RX3, P2RX6, P2RX2 | GPR119 315/4885ACHE 399/4885GABRA5 451/4885 |
| US-10611768-B2 | P2X3 and/or P2X2/3 compounds and methods | P2RX3, P2RX6, P2RX2 | GPR119 315/4885ACHE 399/4885GABRA5 451/4885 |
| US-10174039-B2 | P2X3 and/or P2X2/3 compounds and methods | P2RX3, P2RX6, P2RX2 | GPR119 315/4885ACHE 399/4885GABRA5 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.